Arş. Gör. ENES ERUL

Yayın Ağı

Makaleler 12

1. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review

GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., et al.

ONCOLOGIST , cilt.29, 2024 (SCI-Expanded, Scopus)

2. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

Guven D. C., ERUL E., KAYGUSUZ Y., Akagunduz B., Kilickap S., De Luca R., et al.

Supportive Care in Cancer , cilt.31, sa.12, 2023 (SCI-Expanded, Scopus)

3. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives

ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.

European Archives of Oto-Rhino-Laryngology , cilt.280, sa.8, ss.3541-3556, 2023 (SCI-Expanded, Scopus)

4. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

5. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.

European Archives of Oto-Rhino-Laryngology , cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)

6. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)

7. Knowledge and Attitudes of Turkish Physicians towards Human Monkeypox Disease and Related Vaccination: A Cross-Sectional Study

ŞAHİN T. K., ERUL E., AKSUN M. S., SÖNMEZER M. Ç., ÜNAL S., AKOVA M.

Vaccines , cilt.11, sa.1, 2023 (SCI-Expanded, Scopus)

8. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)

9. Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma

ERUL E., Guven D. C., ÖZBAY Y., ALTUNBULAK A. Y., KAHVECİOĞLU A., ERCAN F., et al.

Biomarkers in medicine , cilt.17, sa.2, ss.87-99, 2023 (SCI-Expanded, Scopus)

10. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.

Frontiers in Molecular Biosciences , cilt.9, 2022 (SCI-Expanded, Scopus)

11. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)

12. Behçet's Disease-related Budd–Chiari Syndrome Successfully Managed with anti-TNF Antibody: A Case Report and Review of the Literature

ERUL E., Uzun G. S., KÖKSAL D., KESKİN O., UYSAL S., İNKAYA A. Ç., et al.

European Journal of Case Reports in Internal Medicine , cilt.9, sa.8, 2022 (Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road

BÖLEK E. Ç., ERUL M. E., YARDIMCI G. K., KILIÇ L., AKDOĞAN A., KARADAĞ Ö.

2019 ACR/ARP Annual Meeting, ATLANTA, Amerika Birleşik Devletleri, 8 - 13 Kasım 2019, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

106

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler